I-Corps: Device for improving lymph circulation in patients with lymphedema
I-Corps: Device for improving lymph circulation in patients with lymphedema
批准号:
2131973
负责人:
Linda Koehler
金额:
$5.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-01 至 2023-11-30
中文摘要
I-Corps项目更广泛的影响/商业潜力是开发一种治疗淋巴水肿患者的设备。根据世界卫生组织的数据,全球有超过2.5亿人患有淋巴水肿,而5-10万美国人患有慢性淋巴水肿。继发性淋巴水肿是最常见的,通常发生在癌症手术和/或接受放射治疗后。高达40%的乳腺癌幸存者有上肢淋巴水肿,高达70%的妇科癌症幸存者和20%的前列腺癌幸存者有下肢淋巴水肿。提出的技术将被设计成一种可穿戴的医疗设备,将刺激淋巴循环和改善软组织组成。该装置将应用交替气动压力来挤出淋巴液,改善淋巴管的功能。与目前的金标准治疗(即压缩衣)相比,其目标是改善淋巴流量,并改善患有淋巴水肿的衰弱效应的患者的生活。I-Corps项目的基础是开发一种医疗设备,通过交替负压和正压梯度来刺激淋巴循环,治疗淋巴水肿患者。先前的研究显示了乳腺癌患者淋巴水肿发展的潜在病理生理学和淋巴系统的结构改变。试验台试验的初步结果证实了该方法在技术和生理上的可行性。该装置将应用交替压力梯度将淋巴液从间质组织转移到淋巴管。这一过程将使健康的淋巴管能够扩张和吸收淋巴液,而目前的压缩方法仅使用气动压力来挤出淋巴液。所提出的技术可以打开受损的淋巴管,并改善淋巴水肿受影响组织对淋巴液的吸收。此外,这项技术可以改善软组织组成,防止纤维化的发展。该奖项反映了美国国家科学基金会的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。
英文摘要
The broader impact/commercial potential of this I-Corps project is the development of a device for the treatment of patients with lymphedema. According to the World Health Organization, lymphedema affects over 250 million people worldwide while 5-10 million Americans suffer from chronic lymphedema. Secondary lymphedema is most common and often occurs after cancer surgery and/or after receiving radiation therapy. Upper extremity lymphedema occurs in up to 40% of breast cancer survivors and lower extremity lymphedema develops in up to 70% of gynecological cancer survivors and 20% of prostate cancer survivors. The proposed technology will be designed as a wearable medical device that will stimulate lymphatic circulation and improve the soft tissue composition. The proposed device will apply alternating pneumatic pressure to squeeze out lymph fluids and improve the function of lymphatic vessels. The goal is to improve lymphatic flow as compared to current gold-standard treatment (i.e., compressive garment) and improve the lives of patients suffering from the debilitative effects of lymphedema.This I-Corps project is based on the development of a medical device for the treatment of patients with lymphedema by alternating negative and positive pressure gradients to stimulate lymphatic circulation. Previous research showed the underlying pathophysiology of lymphedema development and the structural alterations of the lymphatic system in patients with breast cancer. Preliminary results of bench tests with a prototype confirmed the technical and physiological feasibility of the proposed approach. The proposed device will apply alternating pressure gradients to redirect lymphatic fluids from the interstitial tissue to the lymphatic ducts. This process will enable healthy lymphatic vessels to expand and absorb lymph fluid as compared to current compressive methods that only use pneumatic pressure to squeeze out lymph fluids. The proposed technology may enable the opening of damaged lymphatic vessels and improve the absorption of lymph fluid from lymphedema affected tissues. Moreover, this technology may improve soft tissue composition and prevent fibrosis development.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PFI-TT: Developing a Device to Improve Lymphatic Flow
-
批准号:2213912
-
项目类别:Standard Grant
-
资助金额:$25.0万
-
财政年份:2022
-
负责人:Linda Koehler
-
依托单位:
海外基金